Navigation Links
Combination of 2 novel anti-cancer agents may help fight CML resistant to current therapy
Date:5/29/2008

Virginia Commonwealth University Massey Cancer Center researchers have identified that a combination of novel anti-cancer compounds is able to kill chronic myelogenous leukemia cells previously resistant to conventional forms of therapy.

Chronic myelogenous leukemia, or CML, is a cancer of the bone marrow caused by a specific genetic abnormality and is one of the more common forms of leukemia. Imatinib mesylate, or Gleevec, is a highly effective anti-cancer agent that has revolutionized the course of therapy for patients with CML. It works by inhibiting the activity of a mutant protein, known as Bcr/Abl, which is responsible for the disease. However, despite initial success, patients eventually become resistant to imatinib mesylate, often through the development of further mutations in the Bcr/Abl protein.

According to Steven Grant, M.D., Masseys associate director for translational research and co-leader of the cancer centers cancer cell biology program, and senior author of the study, resistance to imatinib mesylate prompted the search for newer agents that are active against the mutated forms of Bcr/Abl. Such agents include MK-0457, a Bcr/Abl kinase inhibitor that also targets another protein called an aurora kinase. Aurora kinase plays an important role in mitosis and cell division. In preclinical studies, MK-0457 is active against the T315I Bcr/Abl mutation, a major cause of imatinib resistance, and has shown promise in early clinical trials, Grant said.

In this study, Grant and colleagues examined the effects of combining MK-0457 with vorinostat, a novel targeted agent that has recently been approved for the treatment of cutaneous T-cell lymphoma. They found that this combination leads to a dramatic induction of apoptosis, or programmed cell death in CML cells, including imatinib-resistant cells bearing the T315I or other mutations. The article was pre-published as a First Edition Paper in Blood, the journal of the American Soci
'/>"/>

Contact: Sathy Achia Abraham
sbachia@vcu.edu
804-827-0890
Virginia Commonwealth University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Promising drug combination may help those with ocular melanoma that has spread
2. Combination therapy reverses effects of portal hypertension in rats
3. Combination vaccines okay for infants, study shows
4. Antidepressants and painkillers - a dangerous combination
5. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Drug combination might offer hope for patients deadly brain tumors
8. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
9. Combination targets: some drugs may work best when they work together
10. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
11. Quality Control: Nissan Quest to Feature micronAir(R) Combination Cabin Air Filters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 Hastings and Hastings, a law ... a record number of legal representation client review requests for ... been a steady rise in the number of slip and ... home throughout the Valley. With that said, a large number ... by an experienced law firm. Hastings and Hastings is a ...
(Date:1/22/2015)... 22, 2015 Liberty University has received accreditation ... program from the Council for Accreditation of Counseling & ... Liberty’s Center for Counseling & Family Studies , is ... the university’s new School of Behavioral Sciences. Prior to the ...
(Date:1/22/2015)... 2015 Woodloch Pines, an all-inclusive family ... by TripAdvisor as the number one best large hotel for ... the world for their annual Travelers’ Choice Awards. , ... The website is home to millions of unbiased and honest ...
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who consistently ... thrilled to have it lead the wedding dress industry into ... prom dresses for the global market. , “The CEO of ... he focuses on continuing the goal of operational excellence and ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2
... efficient to use the drug cetuximab only in colorectal cancer ... a study published online August 7 in the Journal ... tumors harbored wild-type KRAS were found to have a higher ... by the National Cancer Institute of Canada Clinical Trials Group. ...
... Provides Protection for People with Lupus and other Chronic Diseases ... Lupus Foundation of America (LFA) President and Chief Executive Officer, Sandra ... Access to Prescription Medications Act of 2009" introduced on Thursday, ... , , "We support and ...
... , , MORRISTOWN, N.J., Aug. 7 ... specialty pharmaceutical company, announced today that one lot of 100 mcg/hr ... voluntarily recalled from wholesalers and pharmacies. The recalled patches are ... were manufactured by Watson Laboratories, Inc. and distributed by Watson Pharma, ...
... , NEW YORK, Aug. 7 Duane ... Reade Inc. and Duane Reade (collectively, the "Issuers"), had closed ... Secured Notes due August 1, 2015 (the "Notes"). The ... The Notes were priced at 97.417%, representing a yield to ...
... time for decisions, , FRIDAY, Aug. 7 (HealthDay News) -- ... serious complications for themselves and their moms. , Among single-baby ... "breech presentations," with the baby,s bottom, rather than head, positioned ... numbers are small, experts say the risks can be big. ...
... keep new beta cells under control , FRIDAY, Aug. 7 ... that plays a key role in the conversion of pancreas ... to a new treatment for type 1 diabetes. , In ... called Pax4 is turned on in pancreatic cells, the cells ...
Cached Medicine News:Health News:Cost-effectiveness of cetuximab in metastatic colorectal cancer 2Health News:The Lupus Foundation of America Applauds New Legislation that Caps Out-of-Pocket Drug Costs 2Health News:Watson Announces Limited Recall Of Fentanyl Transdermal System 2Health News:Watson Announces Limited Recall Of Fentanyl Transdermal System 3Health News:Duane Reade Holdings, Inc. Announces Closing of Offering of $300 Million of 11.75% Senior Secured Notes Due 2015 2Health News:Duane Reade Holdings, Inc. Announces Closing of Offering of $300 Million of 11.75% Senior Secured Notes Due 2015 3Health News:If Baby Is Breech, Technology Might Help 2Health News:If Baby Is Breech, Technology Might Help 3
(Date:1/23/2015)... , Jan. 23, 2015  MedScope ( www.medscope.org ), ... nominated for a 2015 Connected World magazine ... Response System (mPERS), that can be used anywhere, anytime. ... partner.  In nominating MedScope, Landon ...
(Date:1/23/2015)... all-time hits leader, is the new spokesperson for the topical ... announced. "Pete,s a Hall of Famer in our ... with Myoflex," said Ducere Pharma Chief Executive Officer Chris ... across all generations. The passion and intensity that Pete brought ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Rochester Medical's line ... the intermittent catheters you ... All four product configurations ... and antibacterial hydro - ...
... easy on delicate urethral tissues. ... hydrophilic coating provide nearly friction-free ... It's easy to maintain sterility. ... with its own sterile water, ...
... Rochester Medical's line ... the intermittent catheters you ... All four product configurations ... and antibacterial hydro - ...
... Rochester Medical's line ... the intermittent catheters you ... All four product configurations ... and antibacterial hydro - ...
Medicine Products: